Encephalopathy future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| (2 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Newer investigational and therapeutic modalities are under | Newer investigational and therapeutic modalities are under consideration. | ||
==New Therapies== | ==New Therapies== | ||
Newer modalities of treatment are considered for [[hypoxic encephalopathy]]. These drugs reduce the brain activity and its oxygen requirements. | |||
* Magnesium - blocks NMDA receptor | |||
* | * [[Adenosine]] - decreases glutamate release | ||
* | * [[Vitamin C]] - reduces free radicals | ||
* | * [[Caspase inhibitors]] - Inhibit [[apoptosis]] and prevents death of brain tissue | ||
==References== | ==References== | ||
| Line 17: | Line 17: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 12:30, 24 July 2012
|
Encephalopathy |
|
Diagnosis |
|---|
|
Treatment |
|
Encephalopathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Encephalopathy future or investigational therapies |
|
Encephalopathy future or investigational therapies in the news |
|
Risk calculators and risk factors for Encephalopathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Newer investigational and therapeutic modalities are under consideration.
New Therapies
Newer modalities of treatment are considered for hypoxic encephalopathy. These drugs reduce the brain activity and its oxygen requirements.
- Magnesium - blocks NMDA receptor
- Adenosine - decreases glutamate release
- Vitamin C - reduces free radicals
- Caspase inhibitors - Inhibit apoptosis and prevents death of brain tissue